Whitepaper

Remdesivir In COVID-19
The leading COVID-19 antiviral drug - Remdesivir - proving its value in the treatment of severe as well as moderately affected patients
REMDESIVIR IN COVID-19

More Whitepapers / Newsletters

Adult Onset Still's Disease
Adult Onset Still's Disease

Affecting the entire body, Adult Onset Still's disease (AOSD) is a rare type of inflammatory arthritis that affects most people before the age of 45. The symptoms of the disease usually begin with a...

Cancer Care In The Time Of COVID
Cancer Care In The Time Of COV...

The coronavirus outbreak has affected thousands of people in at least 186 countries which has also affected the cancer care delivery system apart from affecting the overall health system. Cancer patie...

Complex Regional Pain Syndrome Newsletter
Complex Regional Pain Syndrome

A chronic pain condition, Complex Regional Pain Syndrome (CRPS) often affects one limb and is believed to be caused by injury, or malfunction of, the peripheral and central nervous systems. DelveInsig...

Duchenne Muscular Dystrophy Newsletter
Duchenne Muscular Dystrophy

A genetic disorder, Duchenne Muscular Dystrophy (DMD), is a progressive form of muscular dystrophy with a higher preponderance in males; however, in some rare cases, it can occur in females too. As pe...

ASCO: Evolution of Precision Medicine
Let Us Hear From ASCO: Evoluti...

Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailoring the treatment approach and regiment cancer patients are administered. Unlike traditional chemothe...